Skip to main content

ORIGINAL RESEARCH article

Front. Cardiovasc. Med.
Sec. Pediatric Cardiology
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1472663

Outcomes of HeartMate 3 in Pediatric Patients with End-Stage Heart Failure: A Single-Center Preliminary Experience from Turkey

Provisionally accepted
Eser Doğan Eser Doğan 1*Zulal Ulger Tutar Zulal Ulger Tutar 1Osman Nuri Tuncer Osman Nuri Tuncer 2Reşit e. levent Reşit e. levent 1çağatay engin çağatay engin 2tahir yağdı tahir yağdı 2yüksel atay yüksel atay 2mustafa özbaran mustafa özbaran 1
  • 1 Department of Pediatric Cardiology, Faculty of Medicine, Ege University, Bornova, Türkiye
  • 2 Department of Cardiovascular Surgery, Faculty of Medicine Ege University, Bornova, İzmir, Türkiye

The final, formatted version of the article will be published soon.

    Objectives: We aim to evaluate our initial experience with the HeartMate 3 (HM3) device (Abbott, USA) for palliating pediatric patients with end−stage heart failure (ESHF). Methods: We conducted a retrospective review of clinical data from pediatric patients (aged 7−to−18 years) who underwent HM3 implantation for ESHF at our institution between 2022 and 2024. Patient demographics and follow−up data were comprehensively analyzed. Results: We identified 11 patients (45% males) with a median age of 14 years (IQR 11−17), a median weight of 47 kg (IQR 28−50), a median height of 159 cm (IQR 135−165), and a median body surface area of 1.36 m² (IQR 1.07−1.53) at the time of the intervention. All patients were diagnosed with dilated cardiomyopathy and categorized with PEDIMACS profiles ranging from one to three. The median ICU stay was 14 days (IQR 6−32), with 11 patients receiving inotropic support for a median of four postoperative days (IQR 3−8). The median follow−up period was 150 days (IQR 90−210). Early complications included two cases of pleural effusion, 1 case of cardiac tamponade, 3 cases of polyuria, and one instance of positive blood cultures. One patient, who was non−compliant with warfarin therapy, developed a thrombus in the right atrium that was resolved with a revision of anticoagulant therapy, and did not experience pump thrombosis. During follow−up, one patient died after 28 days from sepsis, one underwent heart transplantation after 10 days, and nine patients remained alive on the device. Notably, there were no reported cases of pump thrombosis, ischemia, or stroke post− implantation. Conclusions: The HM3 device appears to be a safe and effective palliative option for pediatric patients with ESHF.

    Keywords: Cardiac Transplant, Heart Failure, HeartMate 3, pediatric, Turkey

    Received: 29 Jul 2024; Accepted: 27 Sep 2024.

    Copyright: © 2024 Doğan, Ulger Tutar, Tuncer, levent, engin, yağdı, atay and özbaran. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Eser Doğan, Department of Pediatric Cardiology, Faculty of Medicine, Ege University, Bornova, Türkiye

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.